Bladder Cancer Treatment Guidelines

Introduction to BCG Therapy

The National Comprehensive Cancer Network recommends BCG instillation once a week for 6 weeks, starting 2-3 weeks after transurethral resection of bladder tumor (TUR-B), followed by a rest period of 4-6 weeks and a complete reevaluation 12 weeks after the start of therapy 1
Induction BCG therapy consists of 6 weekly instillations starting 2-3 weeks after TURBT, as supported by the Society for Immunotherapy of Cancer consensus 2

BCG immunotherapy is significantly superior to intravesical chemotherapy in patients with carcinoma in situ (CIS), with higher complete response rates (68.1% vs. 51.5%) and longer response duration, with strong evidence (level 1a-1b) 2, 3
Meta-analysis shows BCG significantly reduces 72-month recurrence rate (RR = 0.70) and 143-month recurrence rate (RR = 0.18) compared to intravesical chemotherapy 2

If a patient cannot tolerate BCG, intravesical mitomycin C may be considered as an alternative therapy, although the evidence for this alternative is limited 1, 3
Pembrolizumab showed a 41% complete response rate at 3 months with a median duration of 16.2 months in patients with BCG-unresponsive CIS 4
Thermochemotherapy with mitomycin C can achieve 2-year disease-free survival in 47% of patients with BCG-unresponsive CIS 4

Regular follow-up with urinalysis and cystoscopy is recommended, every 3-6 months in the first 2 years and at larger intervals thereafter, as supported by the National Comprehensive Cancer Network and the Society for Immunotherapy of Cancer consensus 1, 3, 5
Imaging of the upper urinary tract should be performed every 1-2 years, with annual upper urinary tract imaging considered for high-risk disease like CIS 1, 5, 6
Urine molecular tests for urothelial tumor markers may be considered (category 2B recommendation) 5, 3

Bladder carcinoma in situ (CIS) is categorized as high-risk non-muscle invasive bladder cancer (NMIBC) and requires prompt management, with the recommended first-line treatment being intravesical BCG immunotherapy with induction followed by maintenance for 3 years 2, 7
If there is recurrence after initial intravesical therapy and 12-week evaluation, a second induction course of BCG may be considered, with a maximum of two consecutive courses, as recommended by the National Comprehensive Cancer Network 8, 3, 1, 5
Radical cystectomy is the recommended standard treatment for BCG-unresponsive CIS, providing definitive treatment with the highest cancer-specific survival, although alternative options like pembrolizumab, thermochemotherapy with mitomycin C, and BCG re-induction may be considered for patients unfit or unwilling to undergo RC 2, 4, 1

Complete response is defined as no visible tumor on cystoscopy, negative cytology, and negative biopsies 3
Incomplete response is defined as persistent disease detected on cystoscopy, cytology, or biopsy 3
BCG-unresponsive disease is defined as disease that fails to respond to BCG or recurs shortly after treatment, and requires alternative management, with BCG-refractory disease defined as persistent disease at 3 months after adequate induction, and BCG-relapsing disease defined as recurrence after achieving disease-free state at 6 months 3, 4